Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mazenko

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
Clinical Therapeutics|June 29, 2004
Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging studyKerstin Malmstrom, Aditi Sapre, Heather Couglin, et al.
Clinical Neuropharmacology|October 24, 2017
A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson DiseaseW Joseph Herring, Christopher Assaid, Kerry Budd, et al.
Journal of Clinical Pharmacology|October 1, 2003
An evaluation of the dose-dependent inhibition of CYP1A2 by rofecoxib using theophylline as a CYP1A2 probeKenneth Bachmann, Donald White, Luis Jauregui, et al.
Journal of Pharmaceutical Sciences|August 14, 2014
Understanding and reducing the experimental variability of in vitro plasma protein binding measurementsHaiping Wang, Matt Zrada, Ken Anderson, et al.
Journal of Pharmaceutical and Biomedical Analysis|June 1, 2002
Determination of efavirenz, a selective non-nucleoside reverse transcriptase inhibitor, in human plasma using HPLC with post-column photochemical derivatization and fluorescence detectionC Z Matthews, E J Woolf, R S Mazenko, et al.
Clinical Drug Investigation|May 31, 2007
Pharmacokinetic evaluation of rofecoxib : comparison of tablet and suspension formulationsJules I Schwartz, Patrick J Larson, Arturo G Porras, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 23, 2002
The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjectsRita A Halpin, Arturo G Porras, Leslie A Geer, et al.
Journal of Clinical Pharmacology|September 3, 2004
The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activityNancy G B Agrawal, Catherine Z Matthews, Ralph S Mazenko, et al.
Journal of Clinical Pharmacology|December 19, 2003
Pharmacokinetics of etoricoxib in patients with renal impairmentNancy G B Agrawal, Catherine Z Matthews, Ralph S Mazenko, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Clinical Therapeutics|June 29, 2004
Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging studyKerstin Malmstrom, Aditi Sapre, Heather Couglin, et al.
Clinical Neuropharmacology|October 24, 2017
A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson DiseaseW Joseph Herring, Christopher Assaid, Kerry Budd, et al.
Journal of Clinical Pharmacology|October 1, 2003
An evaluation of the dose-dependent inhibition of CYP1A2 by rofecoxib using theophylline as a CYP1A2 probeKenneth Bachmann, Donald White, Luis Jauregui, et al.
Journal of Pharmaceutical Sciences|August 14, 2014
Understanding and reducing the experimental variability of in vitro plasma protein binding measurementsHaiping Wang, Matt Zrada, Ken Anderson, et al.
Journal of Pharmaceutical and Biomedical Analysis|June 1, 2002
Determination of efavirenz, a selective non-nucleoside reverse transcriptase inhibitor, in human plasma using HPLC with post-column photochemical derivatization and fluorescence detectionC Z Matthews, E J Woolf, R S Mazenko, et al.
Clinical Drug Investigation|May 31, 2007
Pharmacokinetic evaluation of rofecoxib : comparison of tablet and suspension formulationsJules I Schwartz, Patrick J Larson, Arturo G Porras, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 23, 2002
The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjectsRita A Halpin, Arturo G Porras, Leslie A Geer, et al.
Journal of Clinical Pharmacology|September 3, 2004
The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activityNancy G B Agrawal, Catherine Z Matthews, Ralph S Mazenko, et al.
Journal of Clinical Pharmacology|December 19, 2003
Pharmacokinetics of etoricoxib in patients with renal impairmentNancy G B Agrawal, Catherine Z Matthews, Ralph S Mazenko, et al.
Pageof 8